183 related articles for article (PubMed ID: 38409644)
1. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
Kunutsor SK; Balasubramanian VG; Zaccardi F; Gillies CL; Aroda VR; Seidu S; Khunti K
Diabetes Obes Metab; 2024 Jun; 26(6):2069-2081. PubMed ID: 38409644
[TBL] [Abstract][Full Text] [Related]
2. Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.
Kunutsor SK; Zaccardi F; Balasubramanian VG; Gillies CL; Aroda VR; Seidu S; Davies MJ; Khunti K
Diabetes Obes Metab; 2024 May; 26(5):1837-1849. PubMed ID: 38379094
[TBL] [Abstract][Full Text] [Related]
3. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
4. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
Fullerton B; Jeitler K; Seitz M; Horvath K; Berghold A; Siebenhofer A
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD009122. PubMed ID: 24526393
[TBL] [Abstract][Full Text] [Related]
5. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
[TBL] [Abstract][Full Text] [Related]
6. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
BMJ; 2011 Nov; 343():d6898. PubMed ID: 22115901
[TBL] [Abstract][Full Text] [Related]
7. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
[TBL] [Abstract][Full Text] [Related]
8. Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
[TBL] [Abstract][Full Text] [Related]
9. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
[TBL] [Abstract][Full Text] [Related]
10. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Madsen KS; Chi Y; Metzendorf MI; Richter B; Hemmingsen B
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD008558. PubMed ID: 31794067
[TBL] [Abstract][Full Text] [Related]
11. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios.
Prattichizzo F; de Candia P; De Nigris V; Nicolucci A; Ceriello A
Metabolism; 2020 Sep; 110():154308. PubMed ID: 32628943
[TBL] [Abstract][Full Text] [Related]
12. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
13. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2011 Jun; (6):CD008143. PubMed ID: 21678374
[TBL] [Abstract][Full Text] [Related]
14. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
[TBL] [Abstract][Full Text] [Related]
16. Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.
Huang CJ; Wang WT; Sung SH; Chen CH; Lip GYH; Cheng HM; Chiang CE
Diabetes Obes Metab; 2018 Sep; 20(9):2131-2139. PubMed ID: 29722116
[TBL] [Abstract][Full Text] [Related]
17. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.
Ray KK; Seshasai SR; Wijesuriya S; Sivakumaran R; Nethercott S; Preiss D; Erqou S; Sattar N
Lancet; 2009 May; 373(9677):1765-72. PubMed ID: 19465231
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
19. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.
Mattila TK; de Boer A
Drugs; 2010 Dec; 70(17):2229-45. PubMed ID: 21080740
[TBL] [Abstract][Full Text] [Related]
20. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
